Disc Medicine Inc (IRON)

$28.69

-1.33

(-4.43%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Disc Medicine Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 46.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 234.9% return, outperforming this stock by 70.2%

Performance

  • $28.15
    $30.03
    $28.69
    downward going graph

    1.88%

    Downside

    Day's Volatility :6.24%

    Upside

    4.45%

    downward going graph
  • $25.60
    $77.60
    $28.69
    downward going graph

    10.77%

    Downside

    52 Weeks Volatility :67.01%

    Upside

    63.03%

    downward going graph

Returns

PeriodDisc Medicine IncIndex (Russel 2000)
3 Months
-57.93%
0.0%
6 Months
-33.37%
0.0%
1 Year
2.1%
-1.2%
3 Years
164.67%
-19.2%

Highlights

Market Capitalization
708.1M
Book Value
$14.17
Earnings Per Share (EPS)
-3.42
Wall Street Target Price
57.11
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.05%
Return On Equity TTM
-29.3%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-91.0M
Diluted Eps TTM
-3.42
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.67
EPS Estimate Next Year
-5.26
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.82

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Disc Medicine Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 99.06%

Current $28.69
Target $57.11

Technicals Summary

Sell

Neutral

Buy

Disc Medicine Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Disc Medicine Inc
Disc Medicine Inc
-56.79%
-33.37%
2.1%
164.67%
137.11%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Disc Medicine Inc
Disc Medicine Inc
4.9
NA
NA
-4.67
-0.29
-0.2
NA
14.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Disc Medicine Inc
Disc Medicine Inc
Buy
$708.1M
137.11%
4.9
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Company Information

disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.

Organization
Disc Medicine Inc
Employees
74
CEO
Dr. Donald William Nicholson Ph.D.
Industry
Healthcare

FAQs